Identification of PNET immunogenic antigens and isolation of tumor-specific T cells, accomplished by selecting for activity markers and/or PDCD1 (70), may augment synergy with other cancer immunotherapy approaches, including adoptive T cell therapies. This evidence concerns the gene PDCD1 and cancer.